1. China Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
Shanghai MicroPort EP Medtech Co., Ltd. Class A

Shanghai MicroPort EP Medtech Co., Ltd. Class A

SSSE:688351
17.19
CNY
-0.19
(-1.09%)
0.14EPS
166.51P/E
10.66BMarket Cap
Oct 30Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.74
0.67
0.9
0.28
0.33
0.37
0.47
0.62
0.7
0.88
0.99
1.11
Basic EPS, GAAP
-0.33
-0.27
-0.21
-0.01
-0.04
0.01
-0.03
0.01
0.01
0.11
0.11
0.14
Free Cash Flow per Basic Share
-1.02
-0.11
-0.31
- -
-0.03
-0.06
-0.04
-0.1
-0.17
0.05
-0.07
- -
Dividend per Share
- -
- -
0.02
0.01
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1.1
1.05
0.85
0.85
2.88
1.45
1.47
3.56
3.58
3.7
3.83
3.85
Tangible Book Value per Share
0.46
0.42
0.28
0.36
2.53
1.32
1.29
3.38
3.36
3.45
3.53
3.54
Basic Weighted Avg Shares
51
69
69
304
357
383
400
421
470
471
471
471
Sales/Revenue/Turnover
37
46
62
84
117
141
190
260
329
413
465
523
Operating Margin (%)
-40.09
-45.91
-19.32
-1.25
-12.9
2.73
-7.88
-2.38
-5.7
8.56
8.4
8.04
Depreciation Expense
1
6
7
8
9
10
15
17
29
37
36
- -
Net Income, GAAP
-17
-19
-14
-2
-15
6
-12
3
6
52
51
64
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.11
0.51
0.15
Profit Margin (%)
-45.47
-40.3
-23.3
-1.99
-12.88
4.06
-6.3
1.18
1.73
12.6
11
12.25
Working Capital
13
15
26
5
191
473
462
1,530
1,423
1,469
1,394
1,373
LT Debt
- -
- -
22
- -
- -
12
9
20
17
8
1
2
Total Equity
77
73
60
60
249
579
590
1,676
1,685
1,742
1,802
1,814
Return on Invested Capital (%)
- -
- -
- -
- -
- -
1.37
- -
- -
- -
3.14
2.99
3.72
Return on Capital (%)
- -
- -
- -
- -
- -
1.36
- -
- -
- -
3.05
2.88
3.58
Return on Common Equity (%)
- -
-24.67
-21.71
-2.8
-9.81
1.39
-2.05
0.27
0.34
3.04
2.88
3.58

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4
4
3
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
471
471
471
Market Capitalization
10,894
10,316
10,664

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,553
1,565
1,560
Cash, Cash Equivalents & STI
1,303
1,278
1,239
Accounts Receivable, Net
78
95
97
Inventories
159
168
203
Total Current Liabilities
159
159
187
Payables & Accruals
- -
- -
- -
ST Debt
4
4
3
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
61.93%
38.7%
3.47%
Free Cash Flow
-84.34%
-28.02%
-233.24%
Net Income, GAAP
103.01%
92.89%
-1.9%
Sales/Revenue/Turnover
28.98%
27.18%
12.43%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
89
109
93
122
413
2025
104
120
- -
128
465
2026
126
149
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.03
0.05
0.02
0.11
2025
0.04
0.03
- -
0.02
0.11
2026
0.06
0.02
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sun Yi Yong
Full Time Employees
523
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
Shanghai China
IPO Date
Aug 31, 2022
Website
everpace.com
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
Shanghai MicroPort EP Medtech Co., Ltd. is a China-based medical technology company that develops, manufactures, and commercializes electrophysiology interventional devices and cardiac ablation systems for the diagnosis and treatment of cardiac arrhythmias. Founded in 2010 and headquartered in Shanghai, China, the company operates as an associated entity of MicroPort Scientific Corporation and listed its Class A shares on the Shanghai Stock Exchange STAR Market in August 2022 under the ticker 688351. MicroPort EP provides integrated electrophysiology solutions across three core ablation energy modalities, including radiofrequency ablation, cryoablation, and pulsed field ablation. Its comprehensive product portfolio comprises 3D cardiac electrophysiology mapping and navigation platforms, notably the proprietary Columbus 3D EP Navigation System; radiofrequency ablation systems, including FireMagic and FireMagic TrueForce 3D irrigated and temperature-controlled cardiac radiofrequency ablation catheters, as well as OptimAblate radiofrequency generators and irrigation pumps; cryoablation technologies, including IceMagic cryoablation balloon catheters and consoles; pulsed field ablation systems, featuring the PulseMagic and PulseMagic TrueForce pressure-sensing pulsed field ablation catheters; diagnostic mapping catheters, including EasyFinder steerable and fixed-curve diagnostic catheters, and EasyLoop circular mapping catheters; and interventional vascular access and procedural accessories, including PathBuilder transseptal puncture kits, steerable guide sheaths, external reference patches, and connection cables. The company markets its products to hospitals, cardiology centers, and electrophysiology laboratories domestically across mainland China and internationally across more than 30 countries and regions in Europe, Latin America, the Middle East, and the Asia-Pacific region. In recent developments, MicroPort EP has advanced its multi-energy electrophysiology portfolio through key regulatory milestones and strategic collaborations, including obtaining National Medical Products Administration approval in China for its IceMagic CryoAblation System and PulseMagic TrueForce pulsed field ablation catheter, securing European CE Mark and UKCA certifications for its FireMagic TrueForce ablation catheter, and expanding its strategic partnership with Stereotaxis to exclusively distribute Robotic Magnetic Navigation systems in China while integrating robotic navigation capabilities into the Columbus 3D mapping platform.